[Serum T3 determination with Seralute. Experimental studies and clinical application].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to N Nagashima.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
BACKGROUND: Vascular endothelial growth factor (VEGF) is thought to be the most potent angiogenic factor in the numerous malignant tumors and a prognostic indicator for cancer patients. Interleukin 12 (IL-12) is a heterodimeric cytokine that has potent anti-tumor and anti-metastatic activities. Recently, it has been suggested that IL-12 regulates VEGF in a murine breast cancer model. MATERIALS AND METHODS: Blood from 26 patients with colorectal cancer was obtained prior to surgery. Plasma levels of VEGF and serum levels of IL-12 were assessed using the quantitative sandwich enzyme immunoassay technique. We investigated the preoperative relationships between plasma levels of VEGF, serum levels of IL-12 and clinicopathological factors in patients with colorectal cancer. RESULTS: Although not statistically significantly, high plasma levels of VEGF and low serum levels of IL-12 tended to occur with more advanced colorectal cancer. Plasma levels of VEGF in patients who had circumferential involvement of the tumor greater than 1/2 were only significantly increased. The preoperative relationship between plasma levels of VEGF and serum levels of IL-12 tended to be negatively correlated. CONCLUSION: These results suggest that high plasma levels of IL-12 or low serum levels of IL-12 may be observed in more advanced colorectal cancer patients. Thus, these patients may require additional immunochemotherapy after surgery. IL-12 may regulate VEGF in the patients diagnosed with colorectal cancer.